Information  X 
Enter a valid email address

ValiRx widens FY pretax loss

By BFN News | 07:45 AM | Thursday 16 April, 2015

ValiRx has widened its FY pretax loss to £3.6m, from £2.9m. Revenue was £87,558, from £124,868. Corporate highlights: · Lead drug VAL201 in Phase l/ll dose escalation clinical trials in patients with locally advanced or metastatic prostate cancer and other advanced solid tumours at University College London Hospital · Establishment of ValiSeek Limited, a risk-sharing joint venture company with Tangent Reprofiling Ltd, to take VAL401 to mid and late stage clinical trials for the treatment of lung cancer · Detection of GeneICE targeting technologies and compounds accelerating through collaboration with world-renowned R&D institution, the German Cancer Research Centre, to bring personalised cancer treatment from laboratory to bedside · Grant of new European and Japanese patents for ValiRx's novel cancer screening test biomarker, NAV3, further extending the geographic reach of the Company's intellectual property in a global cancer/tumour profiling market, which is forecast to grow at a CAGR of 18.5% to reach $US35 billion by 2018* · Raise of £0.8m (before expenses) in equity finance in Q4 Story provided by

a d v e r t i s e m e n t